News Details

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

About Chiasma, Inc.
  • NASDAQ: $CHMA
  • Notified: $6.46
  • 13:28 EDT

Price Chart